Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-iFAP is a small molecule radiopharmaceutical designed for Single Photon Emission Computed Tomography (SPECT) imaging of the tumor microenvironment and cardiac remodeling. It consists of a fibroblast activation protein (FAP) inhibitor based on a boronic acid structure, labeled with the radioisotope technetium-99m (99mTc) via a hydrazinonicotinamide (HYNIC) chelator. The agent specifically targets Fibroblast Activation Protein (FAP), which is overexpressed on cancer-associated fibroblasts (CAFs) in the stroma of most human epithelial tumors and on activated fibroblasts in the heart following myocardial infarction. Developed by the Instituto Nacional De Investigaciones Nucleares (ININ) in collaboration with academic institutions like Yale University, 99mTc-iFAP is being evaluated for its ability to detect primary tumor lesions, lymph node metastases, and to quantify active cardiac remodeling post-ischemia reperfusion injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 99mTc-iFAP.